MDWD · MediWound Ltd. Ordinary Shares
View on chartInsiders & Stakes
| SHAMIR NACHUM Director | ▲ Buy | Open Market | 55,815 Shares held | 6/3/2026 | View profile |
| Fox David Morton Director | ▲ Buy | Open Market | 22,283 Shares held | 6/1/2026 | View profile |
| Rubinstein Samuel Director | ▲ Buy | Open Market | 525 Shares held | 9/1/2026 | View profile |
| Hess Shmuel COO & Chief Commercial Officer | ▼ Sell | Open Market | 0 Shares held | 8/27/2026 | View profile |
Transaction History
| Rubinstein Samuel | ▼ Sell | Open Market | 525 | $7K | 9/1/2026 |
| Rubinstein Samuel | ▲ Buy | Open Market | 525 | $7K | 9/1/2026 |
| Hess Shmuel | ▼ Sell | Open Market | 1,979 | $25K | 8/27/2026 |
| Hess Shmuel | ▼ Sell | Open Market | 1,979 | $26K | 8/27/2026 |
| Hess Shmuel | ▼ Sell | Open Market | 1,865 | $24K | 8/26/2026 |
| SHAMIR NACHUM | ▲ Buy | Open Market | 175 | $2K | 6/3/2026 |
| SHAMIR NACHUM | ▲ Buy | Open Market | 5,825 | $82K | 6/3/2026 |
| Fox David Morton | ▲ Buy | Open Market | 1,797 | $25K | 6/1/2026 |
| Fox David Morton | ▲ Buy | Open Market | 1,730 | $25K | 6/1/2026 |
| Fox David Morton | ▲ Buy | Open Market | 10 | $142 | 6/1/2026 |
| Rubinstein Samuel | ▲ Buy | Open Market | 150 | $2K | 5/29/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
MediWound Secures $3.3M U.S. Department of War Grant
MediWound has been awarded an additional $3.3 million by the U.S. Department of War. The funding is intended to advance the development of a room-temperature-stable formulation of its NexoBrid product. This grant supports the company's ongoing research efforts for its lead therapeutic asset.
MediWound Secures $3.3M U.S. Department of War Grant. MediWound has been awarded an additional $3.3 million by the U.S. Department of War. The funding is intended to advance the development of a room-temperature-stable formulation of its NexoBrid product. This grant supports the company's ongoing research efforts for its lead therapeutic asset.